Market stressed about nothing. They already addressed the guidance question 4-5 seperate times in the earnings call. No one listened and the question got asked again. Market so stressed about guidance GO approval probably won't even affect the share price at this point. Market assuming low growth for the year. If they achieve 23 million in sales Q4 (56perent from Q4 2023) that's success for me. AVH has been a few quarters behind at times , I've always pointed this out, and expected some delay.
Ann: AVITA Medical to Announce First Quarter 2024 Results, page-101
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.52 |
Change
0.010(0.40%) |
Mkt cap ! $166.4M | |||
| Open | High | Low | Value | Volume |
| $2.51 | $2.53 | $2.50 | $62.39K | 24.82K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2905 | $2.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.51 | 3800 | 2 |
View Market Depth
| Last trade - 10.21am 24/06/2024 (20 minute delay) ? |
| AVH (ASX) Chart |